Physician profile
Jesus Gomez
NPI 1609873504
$1,248.48
in general payments reported to CMS, 2019-2025
27 companies · $924 in 2025
The $924 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.74 · 2020: $15.61 · 2021: $11.92 · 2024: $281 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.22 |
| Education | $191.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $174.04 | 2024-2025 | Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $112.91 | 2025 | Opdivo, Opdualag |
| Celgene Corporation | $96.92 | 2025 | Reblozyl |
| Sanofi-Aventis U.S. LLC | $92.99 | 2025 | |
| Gilead Sciences, INC. | $84.79 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $76.67 | 2025 | |
| Novartis Pharmaceuticals Corporation | $63.01 | 2025 | |
| Servier Pharmaceuticals LLC | $56.42 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $55.64 | 2024 | Dupixent |
| Astellas Pharma US INC | $38.95 | 2025 | Vyloy, Xtandi |
| Beone Medicines USA, INC. | $35.67 | 2025 | Tevimbra, Brukinsa |
| Blueprint Medicines Corporation | $31.60 | 2025 | Ayvakit |
| Genmab U.S., INC. | $31.37 | 2024 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $30.76 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $29.73 | 2025 | Tagrisso |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.11 | 2025 | Enhertu |
| Dentsply Sirona INC | $23.88 | 2024 | Astra Tech Implant System |
| Aveo Pharmaceuticals, INC. | $23.58 | 2025 | |
| Pfizer INC. | $22.52 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $21.93 | 2025 | Onivyde |
| Abbvie INC. | $19.62 | 2025 | |
| Exelixis INC. | $18.30 | 2025 | Cabometyx |
| Glaxosmithkline, LLC. | $17.53 | 2025 | Jemperli, Zejula |
| Tempus Ai, INC | $17.52 | 2024 | |
| Novo Nordisk INC | $15.74 | 2019 | |
| Merck Sharp & Dohme LLC | $15.61 | 2020 | |
| Biocomposites INC | $13.67 | 2025 | Stimulan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.